Physician profile
Narendranath Epperla
NPI 1902119019
$198,806.03
in general payments reported to CMS, 2019-2025
26 companies · $22K in 2025
The $22K reported for 2025 was more than what 85% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $19K · 2021: $23K · 2022: $53K · 2023: $20K · 2024: $15K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $6,589 · Food and Beverage: $1,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,401.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,835.00 |
| Travel and Lodging | $6,588.63 |
| Food and Beverage | $1,665.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verastem, INC. | $51,031.52 | 2019-2020 | |
| Incyte Corporation | $44,291.57 | 2021-2025 | |
| Beigene USA, INC. | $28,288.41 | 2020-2024 | Brukinsa, Tevimbra |
| Adc Therapeutics America, INC. | $16,198.88 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $12,190.93 | 2025 | |
| Genentech USA, INC. | $9,465.75 | 2024-2025 | Lunsumio, Columvi, Polivy |
| Seagen INC. | $7,731.24 | 2021-2023 | |
| Genzyme Corporation | $5,178.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $5,119.18 | 2021-2024 | Kymriah |
| Abbvie INC. | $4,567.22 | 2025 | |
| Lilly USA, LLC | $3,600.00 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $2,669.42 | 2022-2023 | |
| Karyopharm Therapeutics INC. | $1,625.00 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $1,500.00 | 2019 | |
| Epizyme, INC. | $1,475.00 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Morphosys, US INC. | $1,180.00 | 2021 | |
| Celgene Corporation | $1,075.24 | 2025 | |
| Beigene, Ltd. | $1,008.33 | 2021 | |
| Btg International INC. | $542.80 | 2023-2024 | |
| Beone Medicines USA, INC. | $32.52 | 2025 | Brukinsa |
| Genmab U.S., INC. | $20.52 | 2023 | Epkinly |
| Novo Nordisk INC | $14.50 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narendranath Epperla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.